S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Bangladesh seeks China help to repatriate Rohingya refugees

Biotechnology Stocks

Biotechnology companies leverage cutting-edge science to create medicines and treatments for a multitude of diseases, making them high-risk, high-reward opportunities for investors looking to profit from healthcare innovation. This page lists publicly-traded biotech companies by market capitalization. What is a biotech stock?

MarketRank evaluates a company based on community opinion, dividend strength, institutional and insider ownership, earnings and valuation, and analysts forecasts.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PricePE RatioMarket CapVolumeAverage VolumeIndicator(s)
Thermo Fisher Scientific Inc. stock logo
Thermo Fisher Scientific
31.41$231.06 billion982,4001.52 millionInsider Selling
Novartis AG stock logo
8.36$189.33 billion1.66 million2.47 million
GSK plc stock logo
13.43$82.50 billion3.82 million5.24 millionAnalyst Report
Moderna, Inc. stock logo
5.69$74.32 billion5.43 million6.85 millionEarnings Report
Insider Selling
Analyst Revision
Gap Down
Vertex Pharmaceuticals Incorporated stock logo
Vertex Pharmaceuticals
23.28$73.67 billion2.40 million1.70 millionEarnings Report
Analyst Report
Analyst Revision
BioNTech SE stock logo
3.19$44.50 billion1.58 million1.61 million
Takeda Pharmaceutical Company Limited stock logo
Takeda Pharmaceutical
26.11$43.80 billion1.64 million2.75 million
IQVIA Holdings Inc. stock logo
39.19$43.78 billion678,1001.12 million
Cognizant Technology Solutions Co. stock logo
Cognizant Technology Solutions
15.94$35.82 billion2.00 million3.20 million
Illumina, Inc. stock logo
48.65$35.15 billion747,9001.15 millionUpcoming Earnings
Gap Down
Seagen Inc. stock logo
N/A$32.43 billion708,8001.22 millionAnalyst Upgrade
AmerisourceBergen Co. stock logo
16.21$29.60 billion982,5001.32 millionEarnings Report
Dividend Announcement
Alnylam Pharmaceuticals, Inc. stock logo
Alnylam Pharmaceuticals
N/A$26.24 billion1.36 million889,481Insider Selling
Analyst Revision
Royalty Pharma plc stock logo
Royalty Pharma
55.13$25.77 billion3.65 million2.01 million
argenx SE stock logo
N/A$20.25 billion192,000284,369
BeiGene, Ltd. stock logo
N/A$20.11 billion225,600306,640Gap Up
Catalent, Inc. stock logo
40.06$19.81 billion710,7001.21 million
PerkinElmer, Inc. stock logo
28.79$19.39 billion584,700823,756Earnings Report
ICON Public Limited stock logo
ICON Public
92.51$18.97 billion258,400568,477
Bio-Rad Laboratories, Inc. stock logo
Bio-Rad Laboratories
N/A$16.16 billion84,800212,183
Bio-Rad Laboratories, Inc. stock logo
Bio-Rad Laboratories
N/A$16.01 billion115142Gap Down
Horizon Therapeutics Public Limited stock logo
Horizon Therapeutics Public
21.48$16.00 billion5.97 million2.04 millionEarnings Report
Analyst Downgrade
Analyst Revision
High Trading Volume
Suzano S.A. stock logo
5.57$12.58 billion2.17 million1.29 millionPositive News
Charles River Laboratories International, Inc. stock logo
Charles River Laboratories International
25.91$11.35 billion550,900535,505Earnings Report
Analyst Revision
Alleghany Co. stock logo
32.58$11.26 billion42,200122,533Earnings Report
United Therapeutics Co. stock logo
United Therapeutics
16.78$10.04 billion329,300466,133Earnings Report
Clarivate Plc stock logo
N/A$9.64 billion2.54 million5.40 millionUpcoming Earnings
iShares Biotechnology ETF stock logo
iShares Biotechnology ETF
N/A$8.53 billion2.41 million2.62 million
Legend Biotech Co. stock logo
Legend Biotech
N/A$7.69 billion662,300733,911Positive News
Syneos Health, Inc. stock logo
Syneos Health
25.55$6.98 billion784,100677,639Earnings Report
Analyst Revision
Exelixis, Inc. stock logo
23.39$6.90 billion2.55 million2.42 millionUpcoming Earnings
Ionis Pharmaceuticals, Inc. stock logo
Ionis Pharmaceuticals
N/A$6.48 billion1.51 million1.08 millionUpcoming Earnings
Analyst Revision
Positive News
Lumentum Holdings Inc. stock logo
36.99$6.28 billion484,300927,150
Halozyme Therapeutics, Inc. stock logo
Halozyme Therapeutics
15.09$6.23 billion1.09 million1.03 millionUpcoming Earnings
Azenta, Inc. stock logo
2.37$5.25 billion273,000570,086Upcoming Earnings
Medpace Holdings, Inc. stock logo
28.76$5.14 billion246,000344,228
10x Genomics, Inc. stock logo
10x Genomics
N/A$4.81 billion677,1001.47 millionGap Down
Novavax, Inc. stock logo
N/A$4.71 billion3.54 million5.99 million
Evoqua Water Technologies Corp. stock logo
Evoqua Water Technologies
82.15$4.69 billion548,100859,415
Beam Therapeutics Inc. stock logo
Beam Therapeutics
N/A$4.46 billion1.11 million1.19 millionUpcoming Earnings
Gap Down
Denali Therapeutics Inc. stock logo
Denali Therapeutics
N/A$4.40 billion993,800593,005Upcoming Earnings
Bloom Energy Co. stock logo
Bloom Energy
N/A$4.29 billion4.06 million3.43 millionUpcoming Earnings
Gap Up
Vir Biotechnology, Inc. stock logo
Vir Biotechnology
3.33$3.99 billion771,6001.34 million
Fabrinet stock logo
19.48$3.57 billion174,400193,919Upcoming Earnings
Analyst Downgrade
Abcam plc stock logo
N/A$3.43 billion202,900159,084Gap Down
Amicus Therapeutics, Inc. stock logo
Amicus Therapeutics
N/A$3.41 billion6.40 million3.49 millionEarnings Report
Fate Therapeutics, Inc. stock logo
Fate Therapeutics
N/A$3.23 billion1.16 million1.45 millionAnalyst Revision
Gap Down
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals
N/A$2.61 billion6.07 million4.22 millionEarnings Report
Analyst Report
Gap Down
Immunocore Holdings plc stock logo
N/A$2.39 billion249,900190,188Upcoming Earnings
Krystal Biotech, Inc. stock logo
Krystal Biotech
N/A$2.10 billion356,700197,138Positive News
Hercules Capital, Inc. stock logo
Hercules Capital
145.65$2.04 billion1.60 million1.39 million
Olink Holding AB (publ)
N/A$1.97 billion132,900254,584Upcoming Earnings
Iovance Biotherapeutics, Inc. stock logo
Iovance Biotherapeutics
N/A$1.91 billion4.11 million3.42 millionEarnings Report
Analyst Report
Gap Down
SpringWorks Therapeutics, Inc. stock logo
SpringWorks Therapeutics
N/A$1.82 billion1.17 million806,107Earnings Report
ImmunityBio, Inc. stock logo
N/A$1.79 billion1.39 million1.71 millionUpcoming Earnings
Analyst Revision
Gap Down
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals
N/A$1.69 billion640,3001.09 millionUpcoming Earnings
Insider Selling
News Coverage
Gap Down
3D Systems Co. stock logo
3D Systems
6.31$1.64 billion1.34 million1.68 millionGap Down
Adaptive Biotechnologies Co. stock logo
Adaptive Biotechnologies
N/A$1.63 billion1.58 million1.49 millionEarnings Report
Insider Selling
Gap Down
Sana Biotechnology, Inc. stock logo
Sana Biotechnology
N/A$1.56 billion1.87 million1.42 millionEarnings Report
Positive News
Gap Down
Vaxcyte, Inc. stock logo
N/A$1.51 billion296,700334,533Upcoming Earnings
Insider Selling
REGENXBIO Inc. stock logo
18.16$1.51 billion366,100420,183Analyst Revision
Enanta Pharmaceuticals, Inc. stock logo
Enanta Pharmaceuticals
N/A$1.47 billion219,700244,271
Revance Therapeutics, Inc. stock logo
Revance Therapeutics
N/A$1.43 billion691,600683,341Upcoming Earnings
Phreesia, Inc. stock logo
N/A$1.37 billion356,300612,529Gap Down
Simulations Plus, Inc. stock logo
Simulations Plus
117.34$1.35 billion90,300123,185
Morphic Holding, Inc. stock logo
N/A$1.24 billion404,500337,372Analyst Report
Analyst Revision
Gap Down
ImmunoGen, Inc. stock logo
N/A$1.20 billion3.63 million3.50 millionGap Down
Avid Bioservices, Inc. stock logo
Avid Bioservices
10.46$1.20 billion490,500624,912
Standex International Co. stock logo
Standex International
18.93$1.16 billion50,20048,332Earnings Report
Gap Down
Chinook Therapeutics, Inc. stock logo
Chinook Therapeutics
N/A$1.13 billion673,500487,227Upcoming Earnings
Insider Selling
News Coverage
Rocket Pharmaceuticals, Inc. stock logo
Rocket Pharmaceuticals
N/A$1.02 billion791,800678,508Gap Down
Replimune Group, Inc. stock logo
Replimune Group
N/A$1.01 billion295,500317,815Earnings Report
Analyst Report
News Coverage
Negative News
Gap Down
SomaLogic, Inc. stock logo
N/A$927.86 million847,0001.36 millionUpcoming Earnings
Tekla Healthcare Investors stock logo
Tekla Healthcare Investors
N/A$922.25 million111,300133,530
TG Therapeutics, Inc. stock logo
TG Therapeutics
N/A$899.83 million5.39 million2.87 millionGap Down
Inhibrx, Inc. stock logo
N/A$891.61 million340,800372,852Negative News
Gap Down
Arcellx, Inc. stock logo
N/A$867.42 million503,300225,435Upcoming Earnings
Lockup Expiration
High Trading Volume
Wabash National Co. stock logo
Wabash National
43.42$864.19 million287,000398,250
Zealand Pharma A/S stock logo
Zealand Pharma A/S
N/A$846.79 million2,3005,437Upcoming Earnings
Gap Up
SLR Investment Corp. stock logo
SLR Investment
70.81$814.48 million220,100264,986Dividend Announcement
Analyst Revision
IGM Biosciences, Inc. stock logo
IGM Biosciences
N/A$805.04 million197,300666,317Gap Down
Relmada Therapeutics, Inc. stock logo
Relmada Therapeutics
N/A$785.16 million226,800270,919Upcoming Earnings
908 Devices Inc. stock logo
908 Devices
N/A$784.86 million338,800309,111Upcoming Earnings
Insider Selling
BlackRock TCP Capital Corp. stock logo
BlackRock TCP Capital
13.79$772.92 million443,800240,822Earnings Report
Dividend Announcement
Analyst Revision
News Coverage
Sangamo Therapeutics, Inc. stock logo
Sangamo Therapeutics
N/A$762.77 million1.40 million1.51 millionEarnings Report
Adicet Bio, Inc. stock logo
Adicet Bio
N/A$749.68 million322,300461,442Upcoming Earnings
Insider Selling
Cassava Sciences, Inc. stock logo
Cassava Sciences
N/A$701.42 million1.94 million1.67 million
AnaptysBio, Inc. stock logo
N/A$695.91 million206,600256,866
Century Therapeutics, Inc. stock logo
Century Therapeutics
N/A$687.96 million71,000107,633Upcoming Earnings
Seer, Inc. stock logo
N/A$679.99 million172,600395,786Upcoming Earnings
Gap Down
Quanterix Co. stock logo
N/A$644.82 million392,500336,892Gap Down
Kezar Life Sciences, Inc. stock logo
Kezar Life Sciences
N/A$626.51 million2.05 million1.40 millionUpcoming Earnings
Ocugen, Inc. stock logo
N/A$616.79 million6.05 million9.14 million
Amyris, Inc. stock logo
N/A$607.46 million7.25 million5.86 millionUpcoming Earnings
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics
N/A$590.92 million186,400200,650Gap Down
Dyne Therapeutics, Inc. stock logo
Dyne Therapeutics
N/A$590.92 million186,400200,650Gap Down
Arcturus Therapeutics Holdings Inc. stock logo
Arcturus Therapeutics
N/A$584.65 million525,100603,877Upcoming Earnings
Gap Down
ADC Therapeutics SA stock logo
ADC Therapeutics
N/A$571.79 million226,900230,684Upcoming Earnings
Runway Growth Finance Corp. stock logo
Runway Growth Finance
16.25$570.16 million77,50090,256Positive News
Protagonist Therapeutics, Inc. stock logo
Protagonist Therapeutics
N/A$557.60 million831,0001.06 millionPositive News
Gap Down
The How and Why of Investing in Biotech Stocks

One of the most fascinating and potentially risky sectors to invest in is the biotech sector. This is the sector that includes companies involved in the research and development of therapeutics and vaccines to relieve a myriad of conditions and diseases.

The Covid-19 pandemic brought on by the novel coronavirus in 2020 put the sector squarely in focus. However, due to the unprecedented assistance from the U.S. government through Operation Warp Speed (OWS) it was also an anomaly.

Seasoned investors in the biotech industry understand that products go through a lengthy, rigorous, and expensive testing process. However even when (and if) a drug makes it through that process, the product(s) still have to be approved by the U.S. Food & Drug Administration (FDA) before it can go to market.

And the harsh reality of the biotech sector is that many products will never make it to market, which adds a level of risk to any biotech investment. The good news is there are ways to help minimize the risk by understanding what qualities to look for in biotech stocks.


The biotech sector illustrates the risk-reward of investing in stocks more than almost any other sector. Biotech companies are involved in developing therapeutics and drugs for life-threatening conditions. Many of the companies in this sector are small-cap companies. Some are even penny stocks (meaning they have a stock price of under $5).

Biotech stocks are popular because, if these companies successfully bring a product to market, their stock price could double or more virtually overnight. On the other hand, perhaps no other sector comes with so much risk. The reality is that many of the products that these companies develop never make it out of clinical trials, or get approved by the FDA. And that means that investors can easily lose the majority of their investment.

In this article, we’ll describe what a biotech company is and how it is different from (and in some cases similar to) a pharmaceutical company. We’ll also share a few practical tips that can help you select a biotech stock.

How a Biotech Company Is Different From a Pharmaceutical Company?

The biotech and pharmaceutical sectors are related but more like cousins than siblings. One key point that distinguishes the two sectors is that investing in pharmaceutical companies are about what is and biotech stocks are about what could be. And that changes the risk profile for both.

A pharmaceutical company has revenue coming in from products that are commercially available and have other products in development. Because of this pharmaceutical companies are generally profitable and in some cases offer investors a dividend, which can be a significant part of an investor’s total return.

By contrast, a biotech company is primarily research-driven that are using science to develop a potential therapy or vaccine. Many of these companies are small-cap stocks that are not profitable. And even the small fraction of those that rarely pay a dividend.

Another distinction is that pharmaceutical companies spend a great deal of money in marketing and sales. On the other hand, biotech companies see their strength as being in research and development (R&D).

Where the two sectors overlap is that pharmaceutical companies are increasingly pulling back from research and are looking to partner with biotech firms for innovation. This helps create an opportunity for investors who know what to look for in a biotech stock.

How to Select a Biotech Stock

There’s no sure-fire way to take the risk out of biotech stocks. However, there are certain things you can look for to help manage your risk.

  1. Look for a “hot” area of biotech. This means looking for a company that is doing research for a disease or condition that affects a large segment of the population. However, as an investor, these are the companies that you should be looking for because there will be a high demand for the company’s products. The obvious reason is that the companies that were successful would be able to get a faster return on their significant R&D and licensing efforts.

    For example, during the Covid-19 pandemic companies that were developing vaccine candidates soared. However, investors can also look for biotech firms that are researching treatments for areas such as cancer, AIDS, heart disease and neurological conditions.

    Another reason to look for a hot area of research is that it can lead to breakthrough “orphan” drugs and treatments that – if they are first to market - are typically protected from competition for many years.

  2. Look at the company they keep. Many biotech companies are small-cap companies. This can help them maintain a singular focus. However biotech development is expensive and when smaller companies form collaborations with other companies, it can help provide financial and logistical support. And if one collaborator is good, more is better.

  3. As with many investment opportunities, cash is king. The record pace at which multiple Covid-19 vaccines were developed underscores the length of time it takes to bring a product to market. And that means that you should be looking for companies that have an ample cash reserve. It’s not uncommon for small-cap biotech firms to raise money through secondary share offerings. This can work. However, it comes at the expense of share dilution. Companies that continually need to issue share offerings should raise a caution flag for investors.

  4. It stands to reason that in addition to finding companies that have an ample supply of cash, you also want to find companies that are not overly extended with debt. Companies that are heavily burdened with debt will often need to raise more capital which can lead to an unsustainable spiral.

  5. Look for companies with a deep pipeline of products that are in clinical trials. Many biotech companies have one product candidate. However, that’s a high-risk, high-reward proposition for investors. If that product fails, a company might have no other way to recoup their R&D costs. But companies that have several products in development give themselves multiple bites at the apple.

  6. Just as investors want to look for a deep pipeline, they also want to see market-ready products. A deep pipeline is one thing, but at some point, a company has to be able to bring a product to market. Completing clinical trials on human patients is a good first start. However, that’s only the first step. The product needs approval by the U.S. Food & Drug Administration (FDA). And that can take some time. Nevertheless, getting a drug successfully through clinical trials is a good indicator that a product will come to market sooner rather than later.

  7. Look for biotech stocks that have the potential to rebound quickly. These are typically companies whose stocks are being sold on temporary bad news. The process of getting a drug to market is notoriously complex. Along the line, many speculative investors will trade on the news. However investors can use a temporary drop in share price as a great opportunity to buy on the dip. Of course, you have to believe that the news is actually much ado about nothing. If so, investors can use these opportunities to accumulate additional shares.

  8. Have trust for who is in charge. It’s important that the management team consists of not only business-savvy entrepreneurs but also individuals who have the necessary scientific or medical credentials. This ensures that the company will not only be able to allocate resources towards the most promising products, they will also be able to properly interpret research data and make corrections as necessary.

How to invest in biotech stocks?

The easiest and more popular way to invest in biotech stocks is to buy stocks of individual companies. However, investing in an exchange-traded funds (ETFs) can be a smart way to manage the inherent risk of this sector. There are several biotech ETFs that track an index (a basket) of biotech stocks. Some of the most popular biotech ETFs are:

  • S&P Biotech Select Industry Index (INDEXSP:SPSIBI)
  • NYSE Arca Biotechnology Index (INDEXNYSEGIS:BTK)
  • NASDAQ Biotechnology Index (INDEXNASDAQ:NBI)
  • iShares NASDAQ Biotechnology ETF (NASDAQ:IBB)

The final word on investing in biotech stocks

Investing in biotech stocks can be one of the most profitable sectors for risk-tolerant investors. Biotech companies are engaged in research and development for life-threatening conditions. If these companies are able to successfully bring a product to market, its stock price (which in some cases is trading as a penny stock) can double, triple or move even higher.

However, there’s also a tremendous risk to biotech stocks. The process to get a product approved is lengthy and expensive. And just getting a product through clinical trials is not sufficient. There is still an approval process through the FDA. And, unlike the speed at which Covid-19 vaccines have been approved, this can also be a lengthy process.

To invest in biotech stocks requires knowledge of not only financial fundamentals but also the science and medicine behind the company. Individual investors who have a background in science and medicine may have the ability to separate the contenders from the pretenders.


More Stock Ideas from MarketBeat

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.